Establishment of a clinical cancer genetics program for breast cancer in a resource-limited country; challenges and opportunitiesFRONTIERS IN ONCOLOGYIF3.32024-10-230OAAI
Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive , HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced CountryIMMUNOTARGETS AND THERAPYIF4.42024-09-010OAAI
Genetic counseling and genetic testing for pathogenic germline mutations among high-risk patients previously diagnosed with breast cancer: a traceback approachSCIENTIFIC REPORTSIF3.92024-06-040OAAI
Conditional Use of Serial Serum Tumor Markers CA 15.3 and CEA as Predictors of Disease Relapse in Patients with High-Risk Early-Stage Breast CancerCANCER RESEARCHIF16.62024-05-020PRE
From Clinical Trials to Clinical Practice; Real World Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast CancerCANCER RESEARCHIF16.62024-05-020PRE
Delays in Initiating Anti-Cancer Therapy for Early-Stage Breast Cancer-How Slow Can We Go?JOURNAL OF CLINICAL MEDICINEIF2.92023-07-054OAAI
Challenges and Dilemmas Following a Traceback Approach for Genetic Counseling and Genetic Testing for Pathogenic Germline Mutations among High-Risk Patients Previously Diagnosed with Breast CancerCANCER RESEARCHIF16.62023-03-010PRE
Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancerbreast cancerIF3.42023-01-015OAAI
Breast Cancer in Geriatric Patients: Current Landscape and Future Prospects老年患者的乳腺癌: 现状和未来前景CLINICAL INTERVENTIONS IN AGINGIF3.72022-09-0121OAAI
Thromboembolic events (TEE) in patients with HER2-negative, hormone receptor-positive metastatic breast cancer treated with Ribociclib combined with Letrozole or Fulvestrant. Real-world dataCANCER RESEARCHIF16.62022-02-150PRE
Guideline-based multi-gene panel (MGP) testing for germline pathogenic variants among patients diagnosed with breast cancer: Regional perspectivesCANCER RESEARCHIF16.62022-02-150PRE